摘要
Abstract
Objective:To explore the effects of Denosumab combined with Teriparatide on bone metabolism,serum sclerostin(SOST)and osteopontin(OPN)in patients with postmenopausal osteoporosis.Method:A total of 80 patients with postmenopausal osteoporosis admitted to the Third People's Hospital of Jingdezhen from January 2021 to November 2022 were selected and divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with Denosumab,and the observation group was treated with Denosumab combined with Teriparatide.Bone density(BMD),bone metabolism indexes[osteocalcin(OCN),procollagen type Ⅰ N-terminal propeptide(PⅠNP),β-collagen degradation product(β-CTX),bone alkaline phosphatase(BALP)],sex hormones[estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH)],serum SOST,OPN levels before and after treatment of two groups were compared.Result:After treatment,the bone density of lumbar spine,total hip and femoral neck in observation group were higher than those in control group,the differences were statistically significant(P<0.05).After treatment,OCN,PⅠNP,β-CTX and BALP in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,E2 in observation group was higher than that in control group,LH and FSH were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,SOST and OPN in observation group were lower than those in control group,the differences were statistically significant(P<0.05).Conclusion:Denosumab combined with Teriparatide in the treatment of patients with postmenopausal osteoporosis can effectively increase bone density,improve bone metabolism indexes and sex hormones,and reduce serum SOST and OPN levels.关键词
地舒单抗/特立帕肽/绝经后骨质疏松/骨代谢Key words
Denosumab/Teriparatide/Postmenopausal osteoporosis/Bone metabolism
